# Exicure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exicure

- Industry: Biotechnology
- Headquarters: Chicago, US
- Website: www.exicuretx.com
- Total disclosed funding: $5.4M
- Latest round: Series C (Jan 1, 2016)
- Investors on record: 2

## About

Exicure, Inc. is a biotechnology company based in the US, specializing in innovative gene delivery and RNA-based therapeutics aimed at overcoming challenges in treating genetic disorders and various cancers.Founded in 2011 and headquartered in Chicago, US, Exicure, Inc. focuses on developing advanced gene delivery technologies. The company has completed 13 deals and recently raised USD 5.40 mn in a PIPE funding round from CBI USA, Inc. CEO David Giljohann leads the company, which has not undergone significant pivots in its operational strategy since inception.Exicure specializes in the development of innovative therapeutics that concentrate on gene delivery and RNA-based technologies. Their core products include proprietary platforms that deliver therapeutic agents to target tissues, focusing on genetic disorders and cancers. The technology ensures high specificity and efficiency in targeting diseased cells, addressing limitations seen in traditional treatments. Their solutions are designed for biopharmaceutical companies, research institutions, and healthcare providers in oncology and genetic therapy, with markets spanning North America, Europe, and select areas in Asia.In 2024, Exicure reported a revenue of USD 500,000, with an EBITDA of USD -12,204,000. The company generates revenue through partnerships and collaborations with biopharmaceutical firms and research organizations, involving contractual agreements, milestone payments, and royalties on future sales of products developed using their technology. Their revenue model reflects the extensive research and development involved in their offerings, though specific pricing is not disclosed.Exicure plans to leverage its recent funding to support ongoing development of new therapeutic products aimed at addressing unmet medical needs. They are focused on expanding into additional markets in Europe and Asia by mid-2025. Recent funding will be used to strengthen partnerships and further enhance their research capabilities. All previous VC investors have exited their stake in Exicure, Inc.

## Funding rounds

- Series C, Jan 1, 2016 — Acequia Capital
- Series B, Jul 31, 2013 — AbbVie Ventures
- Series B, Dec 21, 2011, $5.4M — AbbVie Ventures

## Investors

- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series B
- Acequia Capital (https://capitalatlas.ai/funds/acequia-capital) — Series C